Rhelion Life Sciences Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Todd Michael Shapiro
- Full Time Employees
- 104
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1 Adelaide Street East Toronto ON Canada M5C 2V9
- IPO Date
- Jan 8, 2021
- CIK
- 0001836747
- Website
- rhelion.com
- Similar Companies
- Business
- Red Light Holland Corp. (CSE:TRIP; OTCQB:TRUFF) engages in the production, growth, distribution and sale of functional mushrooms, mushroom home grow kits, and premium psilocybin truffles to recreational and emerging medical markets in North America, Europe and the Netherlands; core offerings include iMicrodose and Maka branded magic truffles such as Hollandia, Makanaut, Muskoka, Mexicana, Atlantis, Double Vision, Old Dutch and Utopia varieties; Happy Caps mushroom home grow kits in shiitake, oyster and lion's mane; functional mushroom gummies; MiniChamp home cultivation packages; Mistercap’s wellness products; and related items encompassing cannabidiol products, cannabis seeds, headshop goods, growshop items, cannabis-infused baked goods, Wisdom Truffle figurines and iMicroapp tele-counseling platform. The Toronto-headquartered company, founded in 1982, operates key subsidiaries including wholly-owned Happy Caps Mushroom Farms, SR Wholesale B.V., RLH Netherlands B.V., MiniChamp B.V., AEM (gourmet mushrooms) and Wellness World entities, with production facilities in the Netherlands' Horst region, Canadian farms in New Brunswick, Ontario and Nova Scotia, and partnerships extending to the United States; it serves brick-and-mortar SmartShops, online platforms, major retailers like Costco Canada (82 locations for Happy Caps Mega Block kits), Albertsons/Safeway, Real Canadian Superstore pilots and over 270 Canadian stores via distributors such as Van Noorts. Recent developments encompass full acquisition of Happy Caps minority interest in April 2024; strategic partnership with Trailbridge Mushroom Farms in Oregon for U.S. West Coast distribution in September 2024; expanded Costco Canada reorders totaling over 33,000 Mega Block kits and commitments for 20,000 more in 2025; launch of Health Canada-approved Fun(ctional) Mushroom Gummies (NPN #80137179) on Amazon with stability testing cleared; R&D advancements with FDA-compliant/DEA-registered Irvine Labs including 5kg psilocybin truffle shipments in 2025 for microdosing capsules, potency testing and shelf-life processes; collaboration with Arizona State University on the Psychedelic Genome Project; appointment of Dr. Robin Carhart-Harris as Scientific Advisor; prior partnership with Professor David Nutt and Drug Science for microdosing research; Bitcoin treasury strategy allocating up to $2 million; operational streamlining via sale of Oss retail store, suspension of AEM New Brunswick shiitake production by December 2025 and advanced sale talks for AEM Ontario Peterborough farmland rights at $2.5-2.6 million; and active pursuit of research-driven M&A opportunities as of Q2 2026 results reported November 2025.
Company News
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression
Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder
Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program
Rhelion Life Sciences Reports First Quarter 2027 Results
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design
Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO
Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
Rhelion Life Sciences Corp. Commences Trading Under New Name and Ticker Symbol RHEL on the CSE